Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.

Abstract excerpt

Ninety-eight newly diagnosed cases of PML-RARalpha positive APL were treated with a regimen of single agent ATO. FLT3 activating mutations were seen in 33% and an additional cytogenetic finding was noted in 23.2%. FLT3 activating mutations were significantly associated with a bcr3 PML-RARalpha is...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Arsenic Trioxide
• Share to Arsenicals
• Share to Cytogenetics